TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12020139

Group type: EXPERIMENTAL
Intervention: Manual therapy (specific mobilization techniques)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Physical therapy (exercise therapy)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Continued care by a general practitioner (analgesics, counseling, and education)
Number of subjects: 183
Study: 10776091

Group type: EXPERIMENTAL
Intervention: Venepuncture
Number of subjects: 36

Group type: COMPARATOR
Intervention: Heel prick
Number of subjects: 36
Study: 8551733

Group type: EXPERIMENTAL
Intervention: High-dose ACMF (6 cycles): 130 mg/m2 CPA, 26 mg/m2 MTX, 600 mg/m2 5-FU, 26 mg/m2 ADM
Number of subjects: 190

Group type: COMPARATOR
Intervention: Low-dose ACMF (12 cycles): 65 mg/m2 CPA, 13 mg/m2 MTX, 300 mg/m2 5-FU, 13 mg/m2 ADM
Number of subjects: 190
Study: 2112243

Group type: EXPERIMENTAL
Intervention: D‐penicillamine 10‐12 mg/day
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate 50 mg intramuscularly weekly
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Pulse oral methotrexate 7.5‐15.0 mg weekly
Number of subjects: 103

Group type: COMPARATOR
Intervention: Withdrawal rates due to adverse drug reactions
Number of subjects: 103
Study: 389419

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo normal saline (S) infusion
Number of subjects: 14
Study: 31434498

Group type: EXPERIMENTAL
Intervention: rt-PA treatment combined with fisetin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28229937

Group type: EXPERIMENTAL
Intervention: HD‐atDCS over the left and right M1 (STIM, n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham stimulation (SHAM, n = 15)
Number of subjects: 31
Study: 27177436

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSB)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Interscalene block (ISB)
Number of subjects: 59
Study: 24969577

Group type: EXPERIMENTAL
Intervention: glimepiride
Number of subjects: 40

Group type: COMPARATOR
Intervention: exenatide
Number of subjects: 40

Group type: COMPARATOR
Intervention: sitagliptin
Number of subjects: 40
Study: 22099425

Group type: EXPERIMENTAL
Intervention: Curcumin (1 g/d, n 46)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (n 50)
Number of subjects: 96
Study: 19007835

Group type: EXPERIMENTAL
Intervention: MMRV vaccine (Priorix-Tetra)
Number of subjects: 458

Group type: COMPARATOR
Intervention: MMR+V (Priorix and Varilrix)
Number of subjects: 458
Study: 17967669

Group type: EXPERIMENTAL
Intervention: Rocuronium 50 mg mixed with 8.4% NaHCO(3) 3 mL
Number of subjects: 180

Group type: COMPARATOR
Intervention: Rocuronium only
Number of subjects: 180

Group type: COMPARATOR
Intervention: Rocuronium 50 mg mixed with 0.9% NaCl 3 mL
Number of subjects: 180
Study: 16612275

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 0
Study: 11889777

Group type: EXPERIMENTAL
Intervention: PGE1 25 ng.kg‐1.min‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PGE1 50 ng.kg‐1.min‐1
Number of subjects: 30
Study: 10439741

Group type: EXPERIMENTAL
Intervention: Low hematocrit (aiming for 20%)
Number of subjects: 35

Group type: COMPARATOR
Intervention: High hematocrit (aiming for 30%)
Number of subjects: 35
Study: 8903921

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20‐30 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (30 asymptomatic postmenopausal women)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No-tamoxifen group (25 asymptomatic postmenopausal breast cancer patients)
Number of subjects: 38
Study: 2699011

Group type: COMPARATOR
Intervention: Classical anaesthesia with benzodiazepine‐analgesic (diazepam and fentanyl)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Anaesthesia variant with flunitrazepam and buprenorphine
Number of subjects: 45
Study: 1258812

Group type: EXPERIMENTAL
Intervention: Waking suggestion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Hypnosis
Number of subjects: 7

Group type: COMPARATOR
Intervention: Posthypnotic suggestion
Number of subjects: 7
Study: 31961196

Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 30004255

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) users
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 27056250

Group type: EXPERIMENTAL
Intervention: Gloreha hand rehabilitation glove
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional hand rehabilitation
Number of subjects: 30
Study: 25893536

Group type: EXPERIMENTAL
Intervention: High power
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low power
Number of subjects: 0
Study: 23485954

Group type: EXPERIMENTAL
Intervention: Repeated assessments with the Montgomery‐Åsberg Depression Rating Scale (MADRS) and the self‐rating version (MADRS‐S) at baseline and week 2.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Factors at baseline and week 2 used for prediction modeling.
Number of subjects: 400
Study: 21965767

Group type: EXPERIMENTAL
Intervention: Oxaliplatin scale
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: NCI-CTC sensory scale
Number of subjects: 114
Study: 18077657

Group type: EXPERIMENTAL
Intervention: Tailored print materials accompanied by personalized dietary counseling via lay health advisors (promotoras)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Tailored print materials
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control condition (Spanish language targeted materials)
Number of subjects: 357
Study: 16323382

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (2.0‐4.4 Hz oscillations at 3‐mm amplitude)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (Burst‐transcutaneous electrical nerve stimulation on the nondominant forearm)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Number of subjects: 12
Study: 10334388

Group type: EXPERIMENTAL
Intervention: Group I (19 patients whose Hb values improved after infection)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group II (10 patients with persisting anemia after infection)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group III (8 patients without hepatitis virus markers with Hb > 85 g/L)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group IV (11 patients without hepatitis virus markers with Hb < 75 g/L)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 48
Study: 7492041

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy in the Gamow bag at 1.58 atmospheres absolute pressure (8.5 psi) for 40 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normobaric oxygen through a nonrebreather mask at 15 L/minute for 40 minutes
Number of subjects: 12
Study: 1827105

Group type: EXPERIMENTAL
Intervention: Clarithromycin (2 x 125 mg capsules, 12-hourly)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Penicillin VK (2 x 125 mg tablets, 6-hourly)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 128

Group type: COMPARATOR
Intervention: Penicillin VK
Number of subjects: 128
Study: 6796269

Group type: EXPERIMENTAL
Intervention: Cisplatin with mannitol diuresis
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cisplatin without mannitol diuresis
Number of subjects: 67
Study: 31502323

Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with sufentanil (RS1 group)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Ropivacaine combined with sufentanil (RS2 group)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with dexmedetomidine (RD2 group)
Number of subjects: 160
Study: 28640385

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) consolidation therapy
Number of subjects: 1
Study: 26455521

Group type: EXPERIMENTAL
Intervention: 10 mg daily rosuvastatin
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 23292368

Group type: EXPERIMENTAL
Intervention: Modified Darn Repair (MDR)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Lichtenstein Procedure (LP)
Number of subjects: 227
Study: 22143452

Group type: EXPERIMENTAL
Intervention: Nurse management plus home blood pressure monitor
Number of subjects: 416

Group type: COMPARATOR
Intervention: Home blood pressure monitor only
Number of subjects: 416

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 416
Study: 19317824

Group type: EXPERIMENTAL
Intervention: Staged Diabetes Management (SDM)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No protocols for diabetes care (Control)
Number of subjects: 200
Study: 17302926

Group type: EXPERIMENTAL
Intervention: Oral hygiene measures provided by dental hygienists once every 3 weeks (Group A)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Nursing staff provided daily oral hygiene after hands-on instructions (Group B)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 130
Study: 15145325

Group type: EXPERIMENTAL
Intervention: Twice-daily isophane insulin (Group 2)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Basal/bolus isophane/lispro insulin (Group 3)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Continue tablets (Group 1)
Number of subjects: 57
Study: 11163559

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (200 microg/kg) before aortic cross‐clamp
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normal saline injection)
Number of subjects: 20
Study: 9833044

Group type: EXPERIMENTAL
Intervention: Triple therapy for eradication of Helicobacter pylori for one week
Number of subjects: 125

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 125
Study: 7854555

Group type: EXPERIMENTAL
Intervention: Positive family history for CHD
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study: 28486329

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (300 mg·d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Precooling (immersion in water at 18 ± 0.5° C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Supplementation with precooling
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 28764674

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 352

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 352
Study: 26222430

Group type: EXPERIMENTAL
Intervention: Texting while walking
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cognitive distraction while texting and walking
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Texting and cognitive distraction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal walking
Number of subjects: 30
Study: 24130355

Group type: EXPERIMENTAL
Intervention: Multiple daily insulin analog injections
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional glucose monitoring
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring
Number of subjects: 18
Study: 21354608

Group type: EXPERIMENTAL
Intervention: 2.5% hydrolyzed sodium trimetaphosphate (STMP) applied to artificial carious lesions; bonded with One-Step adhesive and non-adhesive infiltrated specimens; remineralized in PAA-containing simulated body fluid for 4 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups without PAA and STMP; no treatment applied.
Number of subjects: 0
Study: 19695194

Group type: EXPERIMENTAL
Intervention: Ambroxol (4.5 mg/kg in 10 mL normal saline by intravenous injection after skin incision)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (10 mL normal saline)
Number of subjects: 40
Study: 17383313

Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 300

Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 300
Study: 15562083

Group type: EXPERIMENTAL
Intervention: Single-injection paravertebral block (PVB) with bupivacaine 5 mg/mL (1.5 mg/kg)
Number of subjects: 60
Study: 11566623

Group type: EXPERIMENTAL
Intervention: Interleukin-2 therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (HAART)
Number of subjects: 0
Study: 9785067

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 34
Study: 7869705

Group type: EXPERIMENTAL
Intervention: Bogus pipeline condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: No bogus pipeline condition
Number of subjects: 0
Study: 3202506

Group type: EXPERIMENTAL
Intervention: Hot dry air
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cold air
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Room temperature air
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (asthmatic subjects)
Number of subjects: 16
Study: 31929203

Group type: EXPERIMENTAL
Intervention: Kangaroo care (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (control group, n = 30)
Number of subjects: 60
Study: 30672234

Group type: EXPERIMENTAL
Intervention: Long-snake moxibustion therapy, applied on acupoints of the governor vessel (Dazhui to Yaoshu) and bilateral Jiaji, once a day for 7 days, 4 courses total.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine western medication (salazosulfapyridine and NSAIDs), for 7 days, 4 courses total.
Number of subjects: 60
Study: 28108076

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver with positive end-expiratory pressure and low tidal volumes
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no alveolar recruitment maneuvers)
Number of subjects: 90
Study: 26157076

Group type: EXPERIMENTAL
Intervention: Melphalan, prednisone, and thalidomide (MPT‐T)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Melphalan, prednisone, and lenalidomide (mPR‐R)
Number of subjects: 306
Study: 24085784

Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Adefovir
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy donors
Number of subjects: 21
Study: 21961433

Group type: EXPERIMENTAL
Intervention: Baseline tibia BML volume
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Baseline femur BML volume
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Approximate BML volume changes by region
Number of subjects: 107
Study: 18242338

Group type: EXPERIMENTAL
Intervention: Methimazole (n = 25)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Propylthiouracil (n = 18)
Number of subjects: 43
Study: 16845251

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Metalyze
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 184
Study: 12809959

Group type: EXPERIMENTAL
Intervention: Pemirolast
Number of subjects: 93
Study: 11265802

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal myocardial revascularisation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiogenic growth factors
Number of subjects: 0
Study: 8804803

Group type: EXPERIMENTAL
Intervention: Methotrexate 50 mg/m2 intramuscularly followed by misoprostol 800 micrograms vaginally
Number of subjects: 300
Study: 1626037

Group type: EXPERIMENTAL
Intervention: Caffeine (250mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 6383735

Group type: EXPERIMENTAL
Intervention: 0.1 percent amcinonide cream
Number of subjects: 33

Group type: COMPARATOR
Intervention: 0.1 percent halcinonide cream
Number of subjects: 33
Study: 30182359

Group type: EXPERIMENTAL
Intervention: 200 μg/day sodium selenite (GI)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C/day (GII)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (GIII)
Number of subjects: 102
Study: 30130351

Group type: EXPERIMENTAL
Intervention: 15 mg ulipristal acetate daily for 7 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 27456689

Group type: EXPERIMENTAL
Intervention: Guided Internet-delivered cognitive behavioural therapy (CBT) program, consisting of four sessions including psychoeducation, physical activity, and relaxation.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 15
Study: 24722219

Group type: EXPERIMENTAL
Intervention: Pharmacy-based intervention providing HIV risk reduction and social/medical services information during syringe sale
Number of subjects: 88

Group type: COMPARATOR
Intervention: Primary control (recruited IDU syringe customers only)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Secondary control (did not recruit IDUs or deliver intervention activities)
Number of subjects: 88
Study: 23164366

Group type: EXPERIMENTAL
Intervention: POSE program (Promotion Of Sustained Employability)
Number of subjects: 0
Study: 20080842

Group type: EXPERIMENTAL
Intervention: Osteoporosis treatment (risedronate, strontium ranelate, zoledronic acid, denosumab)
Number of subjects: 0
Study: 17396084

Group type: EXPERIMENTAL
Intervention: Video movie about liver biopsy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard information delivery (no video)
Number of subjects: 67
Study: 15361699

Group type: EXPERIMENTAL
Intervention: Leptospirosis ARF patients (group 1, P(creat) >442 micromol/l)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Leptospirosis ARF patients (group 2, P(creat) < or =442 micromol/l)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups of leptospirosis ARF patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 35
Study: 11523637

Group type: EXPERIMENTAL
Intervention: Unwanted sexual activity during childhood (USC)
Number of subjects: 3346
Study: 9565284

Group type: EXPERIMENTAL
Intervention: Group 5 (added semi-annual prophylaxis)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Group 1 (control group)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Group 2 (behavioral training)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Group 3 (added weekly chlorhexidine rinse)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Group 4 (added semi-annual fluoride varnish)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Groups 3, 4, and 5 combined
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 297
Study: 8140926

Group type: EXPERIMENTAL
Intervention: Alendronate sodium (0, 5, 20, and 40 mg) for 6 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 3055001

Group type: EXPERIMENTAL
Intervention: Open group psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Closed group psychotherapy
Number of subjects: 0
Study: 31025287

Group type: EXPERIMENTAL
Intervention: U13 → C13 mutation in the NA gene 3′UTR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other mutations within the UTR
Number of subjects: 0
Study: 30200910

Group type: EXPERIMENTAL
Intervention: 4 cycles of docetaxel+oxaliplatin+capecitabine (DOC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 cycles of DOC followed by chemoradiotherapy (45Gy in combination with weekly paclitaxel and carboplatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 26832339

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 24594871

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU or 40.32 μg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 18
Study: 23075357

Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (ASA) and terbutaline for 9 weeks after embryo transfer and around the time of embryo transfer, respectively.
Number of subjects: 167

Group type: COMPARATOR
Intervention: No adjuvant medication (Control group).
Number of subjects: 167
Study: 19411457

Group type: EXPERIMENTAL
Intervention: Augmented repair with a down‐turned gastrocnemius fascia flap
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple repair (end‐to‐end suture repair with Krackow locking loop technique)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Augmented repair
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple repair
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 17241691

Group type: EXPERIMENTAL
Intervention: Clearlink Y‐type extension sets
Number of subjects: 50

Group type: COMPARATOR
Intervention: Three‐way stopcock luers with standard caps
Number of subjects: 50
Study: 15619404

Group type: EXPERIMENTAL
Intervention: Low-dose paclitaxel-eluting stents
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: High-dose paclitaxel-eluting stents
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo stents
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IVUS percent neointima volume obstruction
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Angiographic late lumen loss
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Follow-up diameter stenosis
Number of subjects: 81
Study: 12688622

Group type: EXPERIMENTAL
Intervention: Stringent environmental control (allergen impermeable covers, hot washing of bedding weekly, HEPA vacuum cleaner, hard floor for nursery)
Number of subjects: 995

Group type: COMPARATOR
Intervention: Normal regime (no stringent environmental control)
Number of subjects: 995
Study: 10097222

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1128
Study: 7581965

Group type: EXPERIMENTAL
Intervention: Oral GHRP-6 (300 micrograms/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intravenous GHRH (GHRH-29, 1 microgram/kg)
Number of subjects: 13
Study: 2101864

Group type: EXPERIMENTAL
Intervention: 50 mg fluconazole per day orally
Number of subjects: 40

Group type: COMPARATOR
Intervention: 800 mg amphotericin B per day orally
Number of subjects: 40
Study: 386062

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: bendrofluazide
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 31891860

Group type: EXPERIMENTAL
Intervention: Alcohol intake (breath alcohol concentration of 0.08 g/dL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 15